Chevy Chase Clinical Research

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis4 trials
• Crohn's disease3 trials
• Fatty liver disease (MASLD/MASH)1 trial

Phase

• Phase 34 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Active, not recruiting4 trials
• Completed2 trials
• Recruiting1 trial

Lead sponsor

• Janssen Research & Development, LLC4 trials
• Eli Lilly and Company1 trial
• Inventiva Pharma1 trial
• Shire1 trial

Running trials

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease1 recruiting

Closed trials

• Completed

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· Phase 3· Eli Lilly and Company· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Shire· Source